Log In
BCIQ
Print this Print this
 

PentaStaph

  Manage Alerts
Collapse Summary General Information
Company GlaxoSmithKline plc
DescriptionPentavalent Staphylococcus aureus vaccine
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine
Latest Stage of DevelopmentPhase I/II
Standard IndicationStaphylococcus
Indication DetailsPrevent Staphylococcus aureus infection
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$47.5M

$20.0M

$26.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

08/10/2009

$47.5M

$20.0M

$26.0M

Get a free BioCentury trial today